COTA

𝗦𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝗮𝗹 𝘀𝘁𝗼𝗿𝘆𝘁𝗲𝗹𝗹𝗶𝗻𝗴 𝗯𝗲𝗰𝗼𝗺𝗲𝘀 𝗺𝗼𝗿𝗲 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝘁𝗵𝗮𝗻 𝗲𝘃𝗲𝗿 𝗶𝗻 𝗔𝗜 𝗲𝗿𝗮 Data tell their own types of stories, and never have these stories been more important than in the age of #AI.  At the annual Joint Statistical Meeting (JSM) held in Portland, Oregon this summer, thousands of statisticians from around the world gathered to share perspectives on how to curate powerful but accurate narratives in an increasingly data-driven world, especially as AI brings questions of ethics, equity, and bias to the forefront. The conference opened with an inspiring story of leadership from the first female, Asian-American President of the American Statistical Association - ASA, Madhumita Ghosh-Dastidar, who also serves as leader of the RAND Statistics Group. Ghosh-Dastidar spoke about how statisticians play a vital role in informing policies and countering misinformation across multiple industries, setting the stage for future leadership from statistics professionals. A proactive, objective approach to working with data will be crucial as national and international regulatory bodies develop guardrails around AI, particularly in healthcare and life sciences where algorithms can have a profound impact on equitable access and outcomes for underserved populations. There were dozens of sessions devoted to these topics throughout the conference, with standing room only in many of the lectures and panels  devoted to #AI.  Attendees seemed particularly eager to address questions of how to use data to get more granular in decision-making, support more robust research, and craft policies that accurately reflect the changing needs of increasingly diverse populations. Laura Fernandes, COTA's Senior Statistical Director, presented a short course on #RWD, where she and FDA statistician Freda Cooner discussed a real-world evidence framework in clinical development in front of an audience from the US, Germany, Taiwan, and elsewhere.  In between sessions, there were many on-the-fly conversations about how AI is going to impact the profession in the near future. People expressed excitement and eagerness to rise to the challenges – and confidence that statistical storytellers will be in high demand going forward as companies across all sectors look to build trusted relationships with consumers while maximizing the value of generative AI and other types of machine learning algorithms. #jsm2024

Internships are one of the most important tools for young people preparing to transition from academia to a full-time career. COTA has a long history of welcoming students from all different backgrounds with widely varied interests over the summer months, giving them the opportunity to work on actual projects right alongside their mentors.  These hands-on experiences help them learn new skills, forge important connections, and build confidence as they explore their passions and actively contribute to COTA’s mission of bringing clarity to cancer care. As back-to-school season draws nearer, we’re putting the spotlight on the budding professionals who joined COTA’s marketing team this summer.  Over the past several months, our interns worked to craft key messaging, collaborate with media, and share the COTA story with the world. Read more about their experience on our blog (link in comments). #interns #summerintern #healthcareinternships Ashley Jewell Sophia Anderson

COTA is delighted to participate in this cross-industry collaboration to demonstrate the power of real-world data in clinical research. A huge thanks to our partners at Friends of Cancer Research for coalescing such an esteemed group so we can improve the way we care for people with cancer.

How do we break through the barriers to expand real-world data use across pharma? ➡ Life science companies are engaged in a never-ending quest to get more effective, safer therapies to patients in a faster and more accessible manner.  ➡ But there are still unexplored areas of opportunity for strengthening – and shortening – the R&D pipeline.  And real-world data is at the top of that list. ➡ While the use of real-world data in clinical trials has increased since the pandemic, we’re still extracting only a fraction of the benefit that rich, curated, multi-modal, real-world information can provide to us. ➡ So the question remains, why aren’t more pharma companies using real-world data as a core component of research and development, especially when evidence is piling up that it can change the way we view drug development and precision medicine? 🔽 Read more on our blog 🔽 link in comments 🔽 #rwd #realworlddata #pharma #oncologyresearch #clinicaltrials

Excited to present for COTA this year at posit::conf(2024) in Seattle, WA! I'll be speaking today during the lightning talk session at 1pm PDT about the R package, rwnavigator, that our CORE team has been building for the past two years (shoutout to Anna Barcellos, Eric Hansen, Jacob Ambrose, Christie (Zettler) Ziff, MPH, Andrew Belli, Laura Fernandes, C. K. Wang, and Ming He!). #positconf2024

Fierce Healthcare's annual Most Influential Minority Executives in Healthcare special report recognizes 10 leaders making a significant impact on healthcare. Read their inspiring stories: https://bit.ly/3Wffa6P ✨Debbie Salas-Lopez, MD, MPH, FACP - Transforming community health by meeting patients in the places and streets where they are, as she oversees Northwell Health’s community and public health strategy ✨Wei-Li Shao - Using digital tools to holistically address chronic conditions, as Omada Health's president. Read more about how Shao played a pivotal role in originating Omada’s enhanced GLP-1 Care Track, which is set to launch by 2025. ✨Dr. Monique Gary, DO, MSc, FACS, FSSO, DO, MSc, FACS, FSSO - Fostering an equitable, whole-person healthcare system from the ground up. "Patients and minority executives are no longer waiting for their name to be called to the decision-making table—we’re building our own and adding more chairs every day." ✨C. K. Wang - Unlocking the power of accurate and diverse data to improve outcomes as a key leader at COTA. By combining frontline oncology experience with AI expertise, Wang has helped COTA harness algorithmic insights in order to accelerate the development, evaluation and approval of more effective and targeted cancer treatments. ✨Charlene Aaron, Ph.D., R.N. - Striving to advance the nursing workforce and enhance care for older adults, as president of OSF HealthCare Colleges of Nursing. In the past year, she has made significant contributions to addressing the nationwide nursing shortage. ✨Kofi Essel, MD, MPH, FAAP - Building the critical link between health and nutrition, as food as medicine director at Elevance Health. Essel is an experienced community pediatrician, speaker and academic, with expertise and national recognition in the areas of addressing gaps in nutrition education medical training, obesity stigma and food insecurity. ✨Vidya Raman-Tangella - Advocating for technology and its power to address unmet needs as chief medical officer at Teladoc Health. Raman-Tangella is a lifelong advocate for technology and its power to address unmet needs. ✨Kara Odom Walker, MD, MPH, MSHS, FAAFP - A population health advocate at Nemours and taking on bold goals to tackle. Under her innovative helm, Nemours continues to be a leader in the national value-based care movement, providing insights around pediatric care models to support accountable care, across the continuum. ✨Tuoyo Louis - Advancing equity through opportunity with bold investments. He co-founded Seae Ventures to invest in early-stage healthcare technology and services companies founded by diverse entrepreneurs including women and those who identify as black, indigenous, and people of color. ✨Cain A. Hayes - Ensuring access for all by putting words into action leading Point32Health as president and CEO. He has made health equity a priority for the organization and is leading initiatives to address inequities head-on.

As more pharma companies leverage AI, what are the most promising use cases? Hear from several industry leaders including COTA CEO Miruna Sasu in this article by Meagan Parrish from PharmaVoice. Miruna shares ways AI can improve our understanding of disease progression and outcomes throughout the patient journey. She notes how the increase of accessible genomic data plus accelerated data processing capabilities will allow us to take a more proactive approach to cancer care. #realworlddata #realworldevidence #pharma #healthcareAI #oncologyresearch https://lnkd.in/eBYA3NvY

COTA's Laura Fernandes will be presenting at the American Statistical Association - ASA's JSM conference next week 💥 🆕 this year - watch onsite film interviews, key highlights of the conference, and participants’ insights and reactions from around the meetings on JSM TV 📺 being broadcast through the conference on YouTube: https://lnkd.in/erEkZRba And don't miss Laura's session, 'The Roadmap for Making Clinical Trials More Diverse and Representative' on Monday, August 5. We can't wait!! #clinicaltrials #realworlddata #datascience

#JSM2024 is less than two weeks away! Philip He (DSI), Andrew Potter (FDA) and I organized this AI/ML session at #JSM2024 with an excellent lineup of speakers with varied perspectives - if you are attending in person do put this down on your agenda for the conference. Shoutout to Bo Huang, PhD, FASA and the ASA Biopharmaceutical Section for sponsoring this session! #AIML #JSM2024

Generative AI is quickly proving itself to be one of the most transformative technologies of our time. But GenAI needs a powerful partner if it’s going to wow users with high-quality, trustworthy, bias-free results: the right training and reinforcement data to help it learn and grow over time.  In healthcare and life sciences, real-world data (RWD) from electronic health records, claims, images, socioeconomic data, and medical devices, is the fuel that allows GenAI to burn its brightest. When this dynamic duo comes together in the right way, it creates opportunities to produce actionable insights that reduce manual work, speed up research, improve care delivery, save costs, and create better outcomes across the entire care continuum. The RWD/GenAI combo is so promising that McKinsey & Company estimates it will create between $60 and $100 billion in annual value across the pharma industry. With such potential to rewrite the way life sciences interacts with its vast data assets, what are some of the specific use cases for bringing RWD and GenAI together in innovative and effective ways? ✅ Accelerating research and discovery of new therapies ✅ Personalizing medicine to enhance equity and maximize positive outcomes ✅ Enhancing approvals, commercialization, and post-market activities Read the full story "How technology’s new power couple will revolutionize life sciences" on COTA's blog. Link in comments 👇 #realworddata #rwd #genai #pharma #healthcareai